Novo Nordisk plans new insulin production plant in Brazil  

Novo Nordisk A/S is to build a USD 200 million insulin production plant in Brazil, capable of supplying export markets around the world

Danish medico concern Novo Nordisk A/S has announced that it is to build a USD 200 million insulin production plant in Brazil, pending agreement of terms with relevant authorities. The plant, to be located in Montes Claros in Minas Gerais state, will be dedicated to formulation, filling and packaging of insulin products for diabetes. Construction is scheduled to begin H1 2004 and the new plant is slated to come on stream in 2007.


The new plant will be built to current international Good Manufacturing Practice (GMP) standards, in order to supply export markets around the world. The investment will also create 500 direct jobs in the local region. Novo Nordisk’s vice president for Latin America and the Caribbean Sérgio Noschang comments “I believe this investment will be the largest ever by a foreign pharmaceutical company in Brazil.”


Novo Nordisk is a world leader in diabetes care. Headquartered in Denmark, Novo Nordisk employs 18,700 people in 68 countries and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.


Link > Novo Nordisk

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×